Literature DB >> 9514411

Effects of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death.

G Kellner-Weibel1, W G Jerome, D M Small, G J Warner, J K Stoltenborg, M A Kearney, M H Corjay, M C Phillips, G H Rothblat.   

Abstract

This study was designed to identify cellular responses associated with free cholesterol (FC) accumulation in model macrophage foam cells. Mouse peritoneal macrophages (MPMs) or J774 macrophages were loaded with cholesteryl esters using acetylated LDL and FC/phospholipid dispersions and were subsequently exposed to an acyl coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. This treatment produced a rapid accumulation of cellular FC. The FC that accumulated due to ACAT inhibition was more readily available for efflux to 2-hydroxypropyl-beta-cyclodextrin (which removes cholesterol from the plasma membrane) than FC in untreated control cells. After a 3-hour exposure to an ACAT inhibitor, a significant increase in phospholipid synthesis was seen, followed by the leakage of LDH after 12 hours of treatment. We also observed, by electron and fluorescence microscopy, morphological indications of both apoptosis and necrosis in cells treated with an ACAT inhibitor. In addition, inhibition of ACAT for 48 hours resulted in the formation of FC crystals in MPMs but not in J774 cells. If compound 3beta-[2-(diethylamino)ethoxy]androst-5-en-17-one (U18666A), which modulates intracellular trafficking of cholesterol, was added together with the ACAT inhibitor, each of the metabolic changes elicited by the accumulation of excess FC was either diminished or eliminated. The protective affect of U18666A was not due to a decrease in cellular FC concentrations, because cells treated with an ACAT inhibitor accumulated similar amounts of FC in the presence or absence of U18666A. Thus, treatment with U18666A results in the sequestering of FC in a pool that prevents it from causing various responses to FC deposition in macrophages. The metabolic changes that were produced when these model foam cells were treated with the ACAT inhibitor parallel the pathological events that have been shown to occur in the developing atherosclerotic plaque.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9514411     DOI: 10.1161/01.atv.18.3.423

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  37 in total

Review 1.  Consequences of cellular cholesterol accumulation: basic concepts and physiological implications.

Authors:  Ira Tabas
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease.

Authors:  Roy G Cutler; Jeremiah Kelly; Kristin Storie; Ward A Pedersen; Anita Tammara; Kimmo Hatanpaa; Juan C Troncoso; Mark P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-15       Impact factor: 11.205

Review 3.  Genetics and molecular biology: macrophage ACAT depletion - mechanisms of atherogenesis.

Authors:  David Akopian; Jheem D Medh
Journal:  Curr Opin Lipidol       Date:  2006-02       Impact factor: 4.776

4.  Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment.

Authors:  Steve Seung-Young Lee; Junjie Li; Jien Nee Tai; Timothy L Ratliff; Kinam Park; Ji-Xin Cheng
Journal:  ACS Nano       Date:  2015-02-16       Impact factor: 15.881

5.  Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.

Authors:  Christopher E Pedigo; Gloria Michelle Ducasa; Farah Leclercq; Alexis Sloan; Alla Mitrofanova; Tahreem Hashmi; Judith Molina-David; Mengyuan Ge; Mariann I Lassenius; Carol Forsblom; Markku Lehto; Per-Henrik Groop; Matthias Kretzler; Sean Eddy; Sebastian Martini; Heather Reich; Patricia Wahl; GianMarco Ghiggeri; Christian Faul; George W Burke; Oliver Kretz; Tobias B Huber; Armando J Mendez; Sandra Merscher; Alessia Fornoni
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

Review 6.  ATP-binding cassette transporter-2 (ABCA2) as a therapeutic target.

Authors:  Warren Davis; Kenneth D Tew
Journal:  Biochem Pharmacol       Date:  2017-12-06       Impact factor: 5.858

7.  Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome.

Authors:  Xiaochen Liu; Gloria Michelle Ducasa; Shamroop Kumar Mallela; Jin-Ju Kim; Judith Molina; Alla Mitrofanova; Sydney Symone Wilbon; Mengyuan Ge; Antonio Fontanella; Christopher Pedigo; Javier Varona Santos; Robert G Nelson; Yelena Drexler; Gabriel Contreras; Hassan Al-Ali; Sandra Merscher; Alessia Fornoni
Journal:  Kidney Int       Date:  2020-07-30       Impact factor: 10.612

8.  Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL.

Authors:  Yong Yang; Yan-Fu Wang; Xiao-Fang Yang; Zhao-Hui Wang; Yi-Tian Lian; Ying Yang; Xiao-Wei Li; Xiang Gao; Jian Chen; Yan-Wen Shu; Long-Xian Cheng; Yu-Hua Liao; Kun Liu
Journal:  J Lipid Res       Date:  2012-10-24       Impact factor: 5.922

Review 9.  Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes.

Authors:  Richard J Cenedella
Journal:  Lipids       Date:  2009-05-14       Impact factor: 1.880

10.  Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages.

Authors:  S Fazio; A S Major; L L Swift; L A Gleaves; M Accad; M F Linton; R V Farese
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.